Change in proportion of participants with adverse effects with a probable causal link to the treatment · infantile nystagmus syndrome
1 finding from 1 review
Adverse effects: astigmatism · people with recurrent corneal erosion syndrome without other corneal basement membrane dystrophy
1 finding from 1 review
Adverse effects: Clinically important general adverse effect ‐ short term (EPSEs requiring medication) · schizophrenia
It is very uncertain whether zuclopenthixol dihydrochloride changes adverse effects: Clinically important general adverse effect ‐ short… compared with risperidone (very low certainty).
1 finding from 1 review
Adverse effects: movement disorders ‐ EPS during 24 hours (only reported if occurred in ≥ 5% of people) · psychosis‐induced aggression or agitation (rapid tranquillisation)
It is very uncertain whether ARIPIPRAZOLE (IM) changes adverse effects: movement disorders ‐ EPS during 24 hours (only… compared with OTHER ANTIPSYCHOTIC: a. HALOPERIDOL (very low certainty).
1 finding from 1 review
Adverse effects: Clinically important general adverse effect (EPSEs requiring medication ‐ medium term) · schizophrenia
It is very uncertain whether zuclopenthixol dihydrochloride changes adverse effects: Clinically important general adverse effect (EPSEs… compared with perphenazine (very low certainty).
1 finding from 1 review
Significant adverse effects: significant bleeding requiring intervention, severe pain, iatrogenic injury · adult patients who underwent primary endoscopic sinus surgery, with a diagnosis of recurrent acute or chronic rhinosinusitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects: one or more adverse events during 24 hours (only reported if occurred in ≥ 5% of people) · psychosis‐induced aggression or agitation (rapid tranquillisation)
It is very uncertain whether ARIPIPRAZOLE (IM) changes adverse effects: one or more adverse events during 24 hours (only… compared with OTHER ANTIPSYCHOTIC: a. HALOPERIDOL (very low certainty).
1 finding from 1 review
Adverse effects: one or more adverse events during 24 hours (only reported if occurred in ≥ 5% of people) · psychosis‐induced aggression or agitation (rapid tranquillisation)
It is very uncertain whether ARIPIPRAZOLE (IM) changes adverse effects: one or more adverse events during 24 hours (only… compared with PLACEBO/NIL (very low certainty).
1 finding from 1 review
Adverse effects (composite: plate exposure, wound infection, sinus tract, wound dehiscence, plate removal) · Adults (>16 years old) undergoing orthognathic surgery
1 finding from 1 review
Resorbable versus titanium plates for orthognathic surgery 2017 · Cochrane All outcomesUp to 24 months postoperatively
SoF row. Adverse effects; 60 participants (1 RCT); Quality of the evidence (GRADE): VERY LOW. Exposure of the plate: both titanium and resorbable groups experienced 2 plate exposures which occurred between the third…
1 study · 60 participants
Very low
Adverse effects (sores in the mouth, cramps, bloating, constipation, flatulence, loose stool or diarrhoea) · adults
1 finding from 1 review
Patterns of adverse effects (sores in the mouth, cramps, bloating, constipation, flatulence, and loose stool or diarrhoea) were similar for both groups. Bader 2013.
1 study · 669 participants
GRADE not reported
Surgically‐related severe adverse effects (grade 3+) ‐ postoperative G3+ events (within 30 days of surgery) · women with advanced ovarian epithelial cancer
Neoadjuvant chemotherapy prior to interval surgery (NACT) probably leads to lower surgically‐related severe adverse effects (grade 3+) ‐ postoperative… compared with surgery followed by chemotherapy (PDS) (moderate certainty).
1 finding from 1 review
Adverse effects ‐ difficulty with concentration/concentration impaired/concentration‐attention difficulties · people with drug‐resistant focal epilepsy
Topiramate probably leads to higher adverse effects ‐ difficulty with concentration/concentration… compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effects/events ‐ extrapyramidal symptoms ‐ medium term Number of instances of extrapyramidal symptoms · psychosis‐induced aggression or agitation
1 finding from 1 review
Adverse effects/events ‐ extrapyramidal symptoms ‐ medium term Number of instances of extrapyramidal symptoms · psychosis‐induced aggression or agitation
It is very uncertain whether benzodiazepines changes adverse effects/events: extrapyramidal symptoms ‐ medium termNumber… compared with placebo (very low certainty).
1 finding from 1 review
Adverse effects/events ‐ extrapyramidal symptoms ‐ medium term Number of instances of extrapyramidal symptoms · psychosis‐induced aggression or agitation
It is very uncertain whether benzodiazepines plus antipsychotics changes adverse effects/events: extrapyramidal symptoms ‐ medium termNumber… compared with antihistamines plus antipsychotics (very low certainty).
1 finding from 1 review
Adverse effects associated with wearing the device (such as pain, discomfort, tenderness or skin irritation, or ear infections) · adults with hearing loss
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Adverse effects during treatment Intervention: Hyperbaric chamber/ 160 millibars versus supplementary oxygen · people suffering from high altitude illness
1 finding from 1 review
Withdrawals due to adverse events · patients with schizophrenia
Summary of findings table ‐ Antipsychotic dose reduction probably leads to higher adverse effect ‐ leaving the study early due to adverse effects ‐… compared with dose continuation (moderate certainty).
1 finding from 1 review
Adverse effects other than ototoxicity (≥ grade 3 according to NCICTCAEv3 criteria) with intravenous platinum · children with cancer treated with platinum‐based therapy
1 finding from 1 review
Severe adverse effects ‐ short term Numbers of participants leaving the studies due to severe adverse effects · patients with schizophrenia
It is very uncertain whether TRIFLUOPERAZINE changes severe adverse effects ‐ short term Numbers of participants leaving… compared with PLACEBO (very low certainty).
1 finding from 1 review